Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 7

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 1
Chunk 7
---
 period ended March 29, 2024 unaudited pro forma net earnings were adjusted to exclude the pretax impact of a $25 million nonrecurring acquisition date fair value adjustment to inventory.

NOTE 3.  NET EARNINGS PER COMMON SHARE

Basic net earnings per common share (“EPS”) is calculated by taking net earnings divided by the weighted average number of common shares outstanding for the applicable period.  Diluted net EPS is computed by taking net earnings increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares.  For the three-month periods ended March 28, 2025 and March 29, 2024, approximately 5.3 million and 442 thousand options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the impact of their inclusion would have been anti-dilutive. 

7

Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions, except per share amounts):Three-Month Period EndedMarch 28, 2025March 29, 2024Numerator:Net earnings $954 $1,088 Denominator:Weighted average common shares outstanding used in Basic EPS716.3 740.6 Incremental common shares from:Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”)4.5 8.0 Weighted average common shares outstanding used in Diluted EPS720.8 748.6 Basic EPS $1.33 $1.47 Diluted EPS $1.32 $1.45 

NOTE 4.  REVENUE

The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 28, 2025 and March 29, 2024 ($ in millions).  Sales taxes and other usage-based taxes collected from customers are excluded from revenue.BiotechnologyLife SciencesDiagnosticsTotalFor the Three-Month Period Ended March 28, 2025:Geographical region:North America(a)$543 $721 $1,318 $2,582 Western Europe566 378 400 1,344 Other developed markets(b)64 123 91 278 High-g